SCHEMBL721465

SCHEMBL721465

COc1ccccc1-n1cc(C)c(CO)n1

nearest known ligand 0.43

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
ADORA3 P0DMS8 3/20 0.43
ADORA1 P30542 2/20 0.43
ATP4A P20648 2/20 0.42
ATP4B P51164 2/20 0.42
RAB9A P51151 1/20 0.42
MEN1 O00255 2/20 0.41
KMT2A Q03164 2/20 0.41
ADORA2A P29274 3/20 0.40
KCNN4 O15554 1/20 0.40
ADRA1D P25100 1/20 0.39
ADRA1A P35348 1/20 0.39
ADRA1B P35368 1/20 0.39
DRD2 P14416 2/20 0.38
DRD3 P35462 2/20 0.38
MGLL Q99685 1/20 0.38
KDM4E B2RXH2 1/20 0.38
ALDH1A1 P00352 1/20 0.38
HPGD P15428 1/20 0.38
HSD17B10 Q99714 1/20 0.38
AVPR2 P30518 1/20 0.38

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL14019469 0.84 ADORA3 (0.41) ADORA3ATP4AATP4BRAB9AADORA2A
SCHEMBL719241 0.81 KDM4E (0.45) ADORA3ADORA1ATP4AATP4BRAB9A
SCHEMBL27852206 0.78 ADORA3 (0.44) ADORA3ADORA1MEN1KMT2AADORA2A
SCHEMBL17619435 0.78 ADORA3 (0.50) ADORA3ADORA1MEN1KMT2AADORA2A
SCHEMBL27834160 0.77 ADORA3 (0.43) ADORA3ADORA1MEN1KMT2AADORA2A
SCHEMBL14435740 0.76 RAB9A (0.57) RAB9AMEN1KMT2ADRD2DRD3
SCHEMBL462829 0.75 NPC1 (0.51) RAB9AKDM4EALDH1A1HPGDHSD17B10
SCHEMBL16815437 0.75 DRD2 (0.42) ADORA3ADORA1ATP4AATP4BKCNN4
SCHEMBL719885 0.75 ALDH1A1 (0.46) ADORA3ADORA1MEN1KMT2AADORA2A
SCHEMBL17619434 0.72 MEN1 (0.55) ADORA3ADORA1RAB9AMEN1KMT2A

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-8436043-B2 Heterocyclic compound TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) 2013-05-07 US disclosed
US-20120270865-A2 HETEROCYCLIC COMPOUND TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) 2012-10-25 US disclosed
US-20120053173-A1 HETEROCYCLIC COMPOUND TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) 2012-03-01 US disclosed
EP-2251326-A1 HETEROCYCLIC COMPOUND Takeda Pharmaceutical Company Limited (JP) 2010-11-17 EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20120053173-A1 HETEROCYCLIC COMPOUND SLC5A2, SLC5A1, IAPP ADORA3 2906/4885ADORA1 2915/4885ATP4A 3287/4885
US-20120270865-A2 HETEROCYCLIC COMPOUND SLC5A2, SLC5A1, IAPP ADORA3 2906/4885ADORA1 2915/4885ATP4A 3287/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.